Adeno‐associated virus‐vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease

Adeno‐associated virus‐vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease

Background A treatment of chronic kidney disease (CKD)‐associated anemia in cats is needed. SB‐001 is an adeno‐associated virus‐vectored (AAV)‐based gene therapeutic agent that is administered intramuscularly, causing the expression of feline erythropoietin. Hypothesis/Objective We hypothesized that...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary internal medicine Vol. 37; no. 6; pp. 2200 - 2210
Main Authors: Vaden, Shelly L., Kendall, Allison R., Foster, Jonathan D., New, Heidi L., Eagleson, Jane S., May, Jacky L., Traas, Anne M., Wilson, Matthew J., McIntyre, Beth H., Hinderer, Christian J., Olenick, Lauren K., Wilson, James M.
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 01-11-2023
Wiley
Subjects:
AAV
Anemia
Antibodies
Blood pressure
Cats
Chronic illnesses
Deoxyribonucleic acid
DNA
Enrollments
Gene therapy
Genomes
Iron
Kidney diseases
red blood cells
renal disease
Surgery
Veterinarians
Veterinary services
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background A treatment of chronic kidney disease (CKD)‐associated anemia in cats is needed. SB‐001 is an adeno‐associated virus‐vectored (AAV)‐based gene therapeutic agent that is administered intramuscularly, causing the expression of feline erythropoietin. Hypothesis/Objective We hypothesized that SB‐001 injection would lead to a sustained increase in PCV in cats with CKD‐associated anemia. Animals Twenty‐three cats with International Renal Interest Society (IRIS) Stage 2 to 4 CKD‐associated anemia were enrolled at 4 veterinary clinics. Methods In a prospective clinical trial, cats were treated with 1 of 3 regimens of SB‐001 (Lo 1.2 × 109 genome copies [GCs] on Day 0; Lo ± Hi [supplemental 2nd dose of 3.65 × 109 GC on Day 42]; Hi 3.65 × 109 GC IM on Day 0) and followed for 70 days. Results A response to SB‐001 at any time between Day 28 and Day 70 was seen in 86% (95% confidence interval 65, 97%) of all cats. There was a significant (P < .003) increase in PCV from Day 0 to Day 28 (mean increase 6 ± 6 percentage points [pp]; n = 21), Day 42 (8 ± 9 pp; n = 21), Day 56 (10 ± 11 pp; n = 17), and Day 70 (13 ± 14 pp, n = 14). Twelve cats were hypertensive at baseline, 4 of which developed encephalopathy during the study. An additional 6 cats became hypertensive during the study. Conclusions and Clinical Importance Results of this study suggest that SB‐001 therapy represents a suitable single injection treatment that can address nonregenerative anemia in cats with CKD. It was generally well tolerated; however, hypertension and encephalopathy developed in some cats as previously described in association with erythropoiesis‐stimulating agent therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0891-6640
1939-1676
DOI:10.1111/jvim.16900